Guobang Pharma Past Earnings Performance
Past criteria checks 4/6
Guobang Pharma has been growing earnings at an average annual rate of 2.4%, while the Pharmaceuticals industry saw earnings growing at 9.1% annually. Revenues have been growing at an average rate of 8.7% per year. Guobang Pharma's return on equity is 8.9%, and it has net margins of 12.3%.
Key information
2.4%
Earnings growth rate
-0.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 10.9% |
| Revenue growth rate | 8.7% |
| Return on equity | 8.9% |
| Net Margin | 12.3% |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Guobang Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 5,714 | 702 | 347 | 188 |
| 30 Jun 24 | 5,432 | 660 | 367 | 186 |
| 31 Mar 24 | 5,278 | 617 | 361 | 181 |
| 31 Dec 23 | 5,349 | 612 | 358 | 191 |
| 30 Sep 23 | 5,661 | 689 | 401 | 225 |
| 30 Jun 23 | 5,827 | 783 | 383 | 208 |
| 31 Mar 23 | 5,955 | 915 | 358 | 213 |
| 31 Dec 22 | 5,721 | 921 | 352 | 198 |
| 30 Sep 22 | 5,405 | 906 | 312 | 184 |
| 30 Jun 22 | 4,966 | 823 | 302 | 173 |
| 31 Mar 22 | 4,539 | 721 | 313 | 154 |
| 31 Dec 21 | 4,505 | 706 | 299 | 155 |
| 30 Sep 21 | 4,273 | 694 | 277 | 146 |
| 30 Jun 21 | 4,317 | 741 | 259 | 143 |
| 31 Mar 21 | 4,449 | 834 | 316 | 170 |
| 31 Dec 20 | 4,206 | 810 | 241 | 137 |
| 31 Dec 19 | 3,802 | 315 | 243 | 124 |
| 31 Dec 18 | 3,279 | 211 | 216 | 103 |
| 31 Dec 17 | 2,905 | 178 | 202 | 95 |
Quality Earnings: 605507 has high quality earnings.
Growing Profit Margin: 605507's current net profit margins (12.3%) are higher than last year (12.2%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 605507's earnings have grown by 2.4% per year over the past 5 years.
Accelerating Growth: 605507's earnings growth over the past year (1.9%) is below its 5-year average (2.4% per year).
Earnings vs Industry: 605507 earnings growth over the past year (1.9%) exceeded the Pharmaceuticals industry -2.5%.
Return on Equity
High ROE: 605507's Return on Equity (8.9%) is considered low.